Welcome to our dedicated page for Bio-Path Hldgs news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Hldgs stock.
Bio-Path Holdings, Inc. (BPTH) generates frequent news as a clinical-stage biotechnology company developing RNAi nanoparticle drugs using its proprietary DNAbilize® liposomal antisense platform. Company announcements focus on progress across its oncology and obesity programs, including clinical trial updates, preclinical data, intellectual property developments, and corporate actions.
News coverage commonly highlights the Phase 2 trial of prexigebersen (BP1001) in acute myeloid leukemia and other blood cancers, where Bio-Path has reported extended treatment durability and complete remissions in elderly AML patients treated with combinations that include prexigebersen. Regular updates also cover the Phase 1/1b trial of BP1001-A in advanced solid tumors, including reports of tumor reduction and stable disease in heavily pretreated gynecologic cancer patients.
Another recurring theme in BPTH news is the exploration of BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients. Press releases describe preclinical studies in muscle and liver cell models showing improved insulin sensitivity and restored insulin signaling, along with milestones in the path toward an Investigational New Drug (IND) application.
Investors following BPTH news will also see updates on BP1002 for relapsed or refractory AML, including venetoclax-resistant patients, and BP1003 targeting STAT3, as well as reports on patent issuances that expand the company’s DNAbilize® intellectual property portfolio. In addition, SEC filings and corporate press releases provide information on financing efforts, operational pauses, leadership changes, and the company’s transition from Nasdaq listing to trading on over-the-counter markets. This news page aggregates these developments so readers can track Bio-Path’s clinical, scientific, and corporate trajectory over time.
Bio-Path Holdings (NASDAQ:BPTH) presented interim results from its Phase 2 study of prexigebersen (BP1001) at the ASCO Annual Meeting on June 1, 2024. The study involves treating acute myeloid leukemia (AML) patients with a combination of prexigebersen, decitabine, and venetoclax. Data from two cohorts were presented: 31 newly diagnosed patients and 38 relapsed/refractory patients.
In Cohort 1, 75% of evaluable newly diagnosed patients achieved complete or partial remission. In Cohort 2, 55% of evaluable relapsed/refractory patients achieved complete or partial remission. Adverse events were consistent with those typically associated with AML treatments, including fatigue, anemia, and neutropenia. Severe adverse events included febrile neutropenia (26%) and sepsis (5%).
Given these promising interim results, Bio-Path plans to continue patient enrollment to meet study targets. The company's DNAbilize® technology shows potential in developing RNAi nanoparticle drugs for various cancers.
Bio-Path Holdings (NASDAQ:BPTH) announced that interim results from its Phase 2 clinical trial of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) will be presented at the 2024 European Hematology Association (EHA) Congress in Madrid. The data indicates that prexigebersen is well-tolerated and shows compelling efficacy in newly diagnosed and relapsed/refractory AML patients, outperforming frontline therapy. Jorge Cortes, M.D., will present these results on June 14, 2024. Bio-Path develops targeted nucleic acid cancer drugs using its DNAbilize® technology. Their pipeline includes BP1002 for blood cancers and solid tumors and BP1003, for which an IND is expected to be filed.
Bio-Path Holdings (NASDAQ: BPTH) announced that it will present interim data from its Phase 2 clinical trial of prexigebersen for Acute Myeloid Leukemia (AML) at the ASCO Annual Meeting from May 31 - June 4, 2024.
The trial, involving prexigebersen combined with decitabine and venetoclax, showed promising results, demonstrating compelling efficacy and good tolerance in newly diagnosed and refractory/relapsed AML patients.
This presentation aims to highlight the potential of prexigebersen within the oncology community and encourage broader clinical participation.
Details of the presentation include: Title - Interim Safety and Efficacy of BP1001 in a Phase II AML Study, Date - June 1, 2024, Time - 8:00 AM CT, Location - McCormick Place, Abstract Number - 6511.
Bio-Path is also advancing other candidates, BP1001-A and BP1002, for various cancers and plans an IND for BP1003 targeting STAT3.
Bio-Path Holdings (NASDAQ: BPTH) announced its Q1 2024 financial results, marking progress in clinical and corporate milestones. The company strengthened its balance sheet with $3.5 million through share offerings and expanded its global patent portfolio. Key achievements include completing the second dose cohort in its Phase 1/1b trial for BP1002 in AML patients and the first dose cohort for BP1002 in lymphoma and CLL patients.
Financially, Bio-Path reported a net loss of $3.2 million, an improvement from the $5.3 million loss in Q1 2023. R&D expenses decreased to $2.3 million, while G&A expenses slightly increased to $1.4 million. The company had $0.2 million in cash as of March 31, 2024.
Bio-Path Holdings, Inc. will announce its first quarter 2024 financial results on May 15, 2024. The company specializes in developing cancer drugs using its proprietary DNAbilize® antisense RNAi nanoparticle technology. Bio-Path's lead product candidate, prexigebersen, is in Phase 2 study for blood cancers, and BP1001-A is in Phase 1/1b study for solid tumors. The company is also evaluating BP1002 for blood cancers and solid tumors, with an IND expected to be filed for BP1003. Bio-Path will host a live conference call to discuss the financial results and provide a business overview.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.